ALPN:NSD-Alpine Immune Sciences, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 8.67

Change

0.00 (0.00)%

Market Cap

USD 0.21B

Volume

0.17M

Average Target Price

USD 20.00 (+130.68%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer. The company has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer. Alpine Immune Sciences, Inc. is headquartered in Seattle, Washington.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-20 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD72.87B 34.32 27.50
REGN Regeneron Pharmaceuticals, Inc

N/A

USD59.07B 21.90 16.92
SGEN Seattle Genetics, Inc

N/A

USD31.48B N/A N/A
MRNA Moderna, Inc

N/A

USD27.57B N/A N/A
RPRX Royalty Pharma plc

N/A

USD25.49B 35.14 9.58
GMAB Genmab A/S

N/A

USD25.19B 27.12 3.06
ALXN Alexion Pharmaceuticals, Inc

N/A

USD24.92B 30.43 27.52
BGNE BeiGene, Ltd

N/A

USD23.57B N/A N/A
IMMU Immunomedics, Inc

N/A

USD19.77B N/A N/A
INCY Incyte Corporation

N/A

USD18.98B 47.64 35.20

ETFs Containing ALPN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 125.78% 88% B+ 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 125.78% 88% B+ 93% A
Trailing 12 Months  
Capital Gain 99.31% 81% B- 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 99.31% 81% B- 90% A-
Trailing 5 Years  
Capital Gain -87.26% 25% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -87.26% 25% F 8% F
Average Annual (5 Year Horizon)  
Capital Gain -11.24% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.24% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 41.74% N/A N/A N/A N/A
Risk Adjusted Return -26.94% N/A N/A N/A N/A
Market Capitalization 0.21B 41% F 41% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 12.21 12% F 10% F
Price / Cash Flow Ratio -5.83 49% F 75% C
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -107.30% 28% F 12% F
Return on Invested Capital -104.75% 24% F 9% F
Return on Assets -24.63% 56% F 16% F
Debt to Equity Ratio 15.30% 57% F 70% C-
Technical Ratios  
Short Ratio 0.10 95% A 94% A
Short Percent 0.07% 99% A+ 96% A
Beta 1.62 44% F 25% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector